Biocon Says Biocon Biologics Secures U.S. Market Entry For Yesafili Biosimilar

Reuters
15 Apr
April 15 (Reuters) - Biocon Ltd ::
*BIOCON LTD - BIOCON BIOLOGICS SECURES U.S. MARKET ENTRY FOR YESAFILI BIOSIMILAR
*BIOCON LTD - YESAFILI TO LAUNCH IN U.S. IN SECOND HALF OF 2026 OR EARLIER
*BIOCON - BIOCON BIOLOGICS, REGENERON EXECUTED SETTLEMENT AGREEMENT TO DISMISS PENDING APPEAL

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 15-APR-202502:44:51.21 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10